Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other financing activities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Other financing activities data on record, last reported at $1000.0 in Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $1000.0; the TTM value through Dec 2025 reached $16000.0, down 30.43%, while the annual FY2025 figure was $16000.0, 30.43% down from the prior year.
  • Other financing activities reached $1000.0 in Q4 2025 per LCTX's latest filing, down from $15000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.3 million in Q2 2023 and bottomed at -$3.2 million in Q4 2022.
  • Average Other financing activities over 5 years is $338666.7, with a median of $729000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: soared 128.34% in 2021, then crashed 96.65% in 2023.
  • A 5-year view of Other financing activities shows it stood at $1.1 million in 2021, then tumbled by 381.64% to -$3.2 million in 2022, then skyrocketed by 139.73% to $1.3 million in 2023, then tumbled by 98.2% to $23000.0 in 2024, then crashed by 95.65% to $1000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $1000.0 in Q4 2025, $15000.0 in Q1 2025, and $23000.0 in Q1 2024.